Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical Cord Blood NK Cell Therapy for Pediatric Neuroblastoma
NCT06631391Phase 1Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2024
- Primary completion
- Nov 2026
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of umbilical cord blood-derived NK cells in neuroblastoma, sponsored by Sun Yat-sen University. Primary endpoint: Safety and tolerability of umbilical cord blood natural killer cell injection. Started Nov 2024; status: recruiting.
02
Drugs
umbilical cord blood-derived NK cells
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT06631391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06631391.